MedPath

Safety and antihypertensive effect of switching from eplerenone to esaxerenone in hypertensive patients.

Not Applicable
Recruiting
Conditions
hypertensive patients
Registration Number
JPRN-UMIN000037722
Lead Sponsor
Tokyo Women's Medical University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
200
Inclusion Criteria

Not provided

Exclusion Criteria

Patients with heart failure. Patients who have taken potassium-sparing diuretics (spironolactone, triamterene, and potassium canrenoate) or potassium preparations during the last 8 weeks. Patients whose serum potassium level exceeded 5.0 mEq/L. Patients with severe renal dysfunction (eGFR <30 mL/min/1.73m2).

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Changes in blood pressure, pulse rate, serum levels of potassium and creatinine, and eGFR.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath